Welcome to our dedicated page for Verve Therapeutics SEC filings (Ticker: VERV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Verve Therapeutics’ gene-editing disclosures can feel like wading through a lab notebook written in legalese. Risk factors span emerging CRISPR regulations, manufacturing hurdles and multi-million-dollar collaboration terms—details scattered across 300-page 10-Ks and frequent 8-Ks after clinical readouts. If you have ever asked, “Where can I find Verve Therapeutics’ quarterly earnings report 10-Q filing?” or needed Verve Therapeutics insider trading Form 4 transactions before a pivotal PCSK9 data drop, this page ends the search.
Stock Titan’s platform pairs every VERV submission—10-K, 10-Q, 8-K, DEF 14A, S-1 and more—with AI-powered summaries that explain trial milestones, cash runway shifts and licensing economics in plain English. Our engine flags Verve Therapeutics Form 4 insider transactions real-time, highlights executive stock awards in the proxy statement, and answers natural questions like “What does Verve report about ANGPTL3 safety?” With instant alerts, you see each filing the moment it hits EDGAR, then skim concise AI notes instead of scrolling hundreds of footnotes.
Use this hub to: monitor management’s conviction through insider buys, compare R&D spending across quarters, track 8-K material events explained such as FDA clearances, and read a Verve Therapeutics annual report 10-K simplified section that links pipeline timelines to financial forecasts. Whether you’re studying understanding Verve Therapeutics SEC documents with AI for diligence or checking a Verve Therapeutics proxy statement executive compensation discussion, our coverage delivers every detail investors need—no biotech PhD required.
Verve Therapeutics has received a tender offer from Eli Lilly through its subsidiary Ridgeway Acquisition Corporation. The offer consists of $10.50 per share in cash plus one non-tradable contingent value right (CVR) worth up to $3.00 per share, contingent on achieving specific clinical milestones.
Key terms of the tender offer include:
- Expiration date: July 23, 2025, at 11:59 p.m. Eastern Time
- Minimum tender condition requires majority of outstanding shares
- CVR payment triggered by first U.S. Phase 3 trial dosing for atherosclerotic cardiovascular disease (ASCVD) product
- CVR milestone must be achieved within 10 years of closing
The deal will proceed as a merger under Delaware law Section 251(h) after tender completion. Key conditions include HSR Act clearance, no legal restraints, and no material adverse effects. As of June 20, 2025, Verve had 89,320,995 shares outstanding.
FAQ
What is the current stock price of Verve Therapeutics (VERV)?
What is the market cap of Verve Therapeutics (VERV)?
What is the primary focus of Verve Therapeutics?
Which genes are targeted by Verve Therapeutics' treatments?
How does Verve's approach differ from traditional cardiovascular treatments?
What clinical trials are currently underway at Verve Therapeutics?
What innovative technologies does Verve utilize in its therapies?
Who can benefit from Verve Therapeutics' treatments?
How does the company ensure safety in its gene editing therapies?
What distinguishes Verve Therapeutics in the biotechnology sector?
